A Study of ABT-165 in Subjects With Solid Tumors
Public ClinicalTrials.gov record NCT01946074. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1/1b open-label study evaluating the safety, pharmacokinetics (PK), and preliminary efficacy of ABT-165 when administered as monotherapy and in combination with paclitaxel or 5-fluoruracil, folinic acid and irinotecan (FOLFIRI) or ABBV-181 with/without paclitaxel in subjects with advanced solid tumors. Enrollment to Cohorts A, B were completed and for Cohorts C and D are recruiting.
Study identification
- NCT ID
- NCT01946074
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 101 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 99 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 8, 2013 (Actual)
- Primary completion
- Sep 28, 2022 (Actual)
- Completion
- Sep 28, 2022 (Actual)
- Last update posted
- Dec 15, 2023
2013 – 2022
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Research Institute - Pima /ID# 105677 | Scottsdale | Arizona | 85258-2345 | — |
| Scottsdale Healthcare /ID# 105678 | Scottsdale | Arizona | 85258-4566 | — |
| University of California, Los Angeles /ID# 141389 | Los Angeles | California | 90095 | — |
| University of California, Davis Comprehensive Cancer Center /ID# 141164 | Sacramento | California | 95817 | — |
| Stanford University School of Med /ID# 123758 | Stanford | California | 94305-2200 | — |
| Illinois Cancer Care, PC /ID# 151970 | Peoria | Illinois | 61615 | — |
| Horizon Oncology Research Center /ID# 138022 | Lafayette | Indiana | 47905 | — |
| Duke Cancer Center /ID# 105679 | Durham | North Carolina | 27710-3000 | — |
| Tennessee Oncology-Nashville Centennial /ID# 143280 | Nashville | Tennessee | 37203-1632 | — |
| Mary Crowley Cancer Research /ID# 123757 | Dallas | Texas | 75230 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01946074, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 15, 2023 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01946074 live on ClinicalTrials.gov.